• LOTTE rent-a-car recommends Gangwon-do spring drive courses—just 1-2 hours from Seoul
• Seoul Station branch operates 24/7, 365 days a year for anytime pickup and return
• Incheon Airport branch offers immediate pickup at airport parking upon arrival—luggage cart support available
• Convenient booking via official website and global partners—fully maintained vehicles with comprehensive insurance

SEOUL, South Korea, Feb. 19, 2026 /PRNewswire/ — LOTTE rent-a-car, Korea’s No.1 car rental brand, proposes scenic drive routes for travelers visiting Korea during the late winter and early spring season.

LOTTE rent-a-car holds the top market share in Korea’s rental car industry and recently received the ‘Best Partner Award’ from global travel platform Klook as the sole Korean rental car company, reaffirming its service competitiveness for international customers. The number of foreign customers using LOTTE rent-a-car continues to grow annually, with foreign customers accounting for 25% of total short-term rental car sales in 2025.

This season’s recommended destination is Gangwon-do. With serene mountain landscapes and crisp fresh air, these drive courses showcase Korea’s distinctive natural scenery. Reachable within 1-2 hours from Seoul, they’re perfect even for travelers with tight schedules.

Wonju offers majestic natural views around Mount Chiaksan alongside Guryongsa Temple, a historic sanctuary with 1,500 years of history, making it a popular destination even among Koreans. Cheorwon is famous for the breathtaking Hantangang River Columnar Jointing Trail, designated as a UNESCO Global Geopark. If time permits, we recommend visiting the DMZ, the world’s only remaining division site.

For those planning a rental car journey, we recommend using LOTTE rent-a-car’s Seoul Station or Incheon Airport branches. Both locations offer excellent accessibility immediately upon arrival and are staffed with personnel specialized in serving foreign customers, ensuring smooth communication.

LOTTE rent-a-car Seoul Station Branch is directly connected to the Incheon International Airport Railroad, resulting in exceptionally high usage by foreign tourists. Located just a 3-minute walk from Seoul Station Exit 15, it operates 24 hours a day, 365 days a year—the only branch in the area to do so—allowing vehicle rental and return anytime regardless of flight schedules. A diverse lineup of globally familiar models including Toyota and Tesla Model Y is available. The branch also offers luggage storage service for up to 24 hours, enabling travelers to enjoy Korea “hands-free” without heavy bags.

Incheon Airport Branch provides even more attentive service for travelers weary from long flights. Customers who complete online payment in advance and submit their IDP beforehand can pick up their vehicle immediately at the airport parking lot without visiting the counter. Service desks are located inside both Terminal 1 and Terminal 2, saving time without the need for separate shuttle buses or transfers. Upon departure, staff escort customers directly from the parking lot to the departure gate, and luggage cart service is available when needed, providing seamless care from arrival to departure.

LOTTE rent-a-car has professional staff capable of foreign language consultation and specialized customer service manuals for international clients. The official website (www.lotterentacar.net) operates in 9 languages including English, Chinese, and Japanese, creating a global environment where international customers can smoothly complete the entire process from vehicle reservation to contract management and consultation. Reservations are also available through global partner platforms including Hertz, Booking.com, Klook, Trip.com, DiscoverCars, and KKday.

When renting from LOTTE rent-a-car, various convenient services can be added for an even more comfortable journey. English GPS navigation is provided free of charge, and car seat rental service is available for customers traveling with infants. For cases where pickup and return locations differ, one-way rental service can be selected to efficiently manage travel routes.

All LOTTE rent-a-car vehicles are maintained at all times by 100% nationally certified professional mechanics. The company also provides peace of mind through its nationwide network offering immediate emergency response systems in case of accidents or breakdowns. Additionally, comprehensive insurance coverage and Collision Damage Waiver (CDW) services operate to ensure customer safety and protection. Depending on the program enrolled, a zero-deductible policy applies, allowing travelers to focus on their journey without accident concerns.

A LOTTE rent-a-car representative stated, “Unlike package tours that move according to fixed schedules, rental car travel offers the advantage of moving freely at desired times and routes. We hope travelers will venture beyond Seoul and Jeju to explore various regions such as Gangwon-do and experience Korea’s hidden charms firsthand.”

LOTTE rent-a-car, as Korea’s leading rental car brand, provides comprehensive mobility services to domestic and international customers through approximately 300 branches nationwide and a global partnership network.

About LOTTE rental

LOTTE rental, the only comprehensive rental company in Korea, provides better value with various business portfolios, including auto mobility services that encompass car life, business solution services that support more effi­cient businesses.

LOTTE rent-a-car is creating an innovative car life as the No.1 car rental brand. LOTTE rent-a-car G car, Korea’s ‑first car-sharing brand, is drawing a better mobility service.

LOTTE rental is moving forward as a mobility leader that connects customers’ precious lives.

For more information about LOTTE rental, please visit: https://www.lotterental.com/

Source

Japan’s Ministry of Health, Labour and Welfare (MHLW) Approves PreemieFort® Enteral Solution as Prescription Medicine in the NICU 

DUARTE, Calif., Feb. 19, 2026 /PRNewswire/ — Prolacta Bioscience® today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved PreemieFort® Enteral Solution, a 100% human milk-based fortifier, as a prescription drug for very low birth weight infants, infants with congenital gastrointestinal disorders or congenital heart diseases, and those recovering from gastrointestinal surgery. This regulatory milestone was achieved in partnership with the Clinigen Group, which serves as Marketing Authorization Holder and distributor in Japan. PreemieFort is currently marketed under the brand name “Humavant” outside of the U.S., Canada, and Japan.  

The landmark regulatory decision validates the critical role of Prolacta’s 100% human milk-based fortifiers for the most fragile infants and sets a powerful precedent for neonatal intensive care units (NICUs) worldwide.  

“Japan’s approval of PreemieFort as a prescription drug reflects the strength of the clinical evidence and the pharmaceutical grade processing that stands up to the rigor of Japan’s stringent regulatory and quality requirements,” said Scott Elster, CEO of Prolacta Bioscience. ”The pivotal Japanese clinical study adds to the extensive evidence supporting the benefits of Prolacta’s exclusive human milk-based diet for critically ill and fragile premature infants.”   

Clinical evidence generated in Japan from the JASMINE trial (“A Randomized, Controlled Study to Assess Growth and Safety of the Exclusive Human Milk Diet (EHMD) in Very Low Birth Weight (VLBW) Infants”) informed Japan’s world-class Pharmaceuticals and Medical Devices Agency’s (PMDA) review.  The Japanese-led phase III, randomized, controlled, open-label, multicenter trial evaluated growth and safety associated with Prolacta’s 100% human milk-based fortifiers, demonstrating significantly better growth in VLBW infants with no change in morbidity or mortality. 

Japan is recognized as a global leader in neonatal care, with among the highest preterm survival rates and lowest rates of necrotizing enterocolitis (NEC),^1,2 a life-threatening intestinal disease primarily affecting premature infants. By granting pharmaceutical approval to PreemieFort, Japan is affirming that Prolacta’s human milk-based fortifiers, free from cow milk, are not simply a nutritional choice but an Rx medicine in the NICU.   

Japan’s approval includes three Prolacta products — PreemieFort Enteral Solution 6, PreemieFort Enteral Solution 8 (Humavant+6 and Humavant+8 human milk-based fortifiers outside the U.S., Canada, and Japan), and PreemieFort Enteral Solution CF (Humavant CR human milk caloric fortifier outside the U.S., Canada, and Japan) — which provide concentrated nutrition to support growth by delivering essential calories and nutrients, while retaining the highest level of human milk bioactivity.  

The approval demonstrates clinical confidence in the benefits and safety of PreemieFort human milk-based fortifiers across a wider range of vulnerable infants with complex nutritional needs.  

“In the NICU, what we feed our smallest patients can influence their entire life,” said Kate Tauber, MD, MA, professor of pediatrics and director of the Human Milk Program at Bernard and Millie Duker Children’s Hospital. “Human milk-based fortifiers should be held to the same expectations as other therapies, consistent, tightly controlled, and safe. Prolacta’s commitment to pharmaceutical-quality manufacturing requirements helps protect vulnerable infants and supports better outcomes.” 

Prolacta maintains the industry’s strictest quality and safety standards for screening, testing, and processing donor milk — standards that extend through pharmaceutical grade product manufacturing. Together, these controls earned Japan’s prescription drug approval, one of the world’s highest regulatory benchmarks.

About Prolacta Bioscience
Prolacta Bioscience® is the global leader in human milk-based nutrition, dedicated to improving health outcomes for critically ill and premature infants. The company’s 100% human milk-based fortifiers and formulas have been used in more than 125,000 vulnerable premature infants worldwide.³ In a global first, Japan granted Prolacta’s PreemieFort® fortifiers prescription drug status in late 2025 for very low birth weight infants, infants with congenital gastrointestinal disorders or congenital heart diseases, and those recovering from gastrointestinal surgery. Prolacta operates pharmaceutical-grade human milk processing facilities and maintains the industry’s strictest quality and safety standards, with more than 20 tests to screen donor milk and the use of vat pasteurization to inactivate pathogens and ensure safety. Its vat pasteurization also preserves the bioactive components of human milk that support immune protection, gut development, and growth — benefits that are especially important for premature and medically fragile infants.^4-6  Vat pasteurization keeps human milk closer to its natural state than other processing methods, while still ensuring safety. Prolacta has built a secure, independent donor milk supply chain supported by long-term partnerships with thousands of rigorously screened donors, ensuring ample supply to meet NICU demand. Prolacta’s products have been evaluated in over 30 peer-reviewed clinical studies, demonstrating the short- and long-term health benefits of its patented human milk-based fortifiers and formulas. Learn more online or at X, Instagram, Facebook, TikTok, and LinkedIn. 

Media Contact:
Loren Kosmont
Lkosmont@prolacta.com
310-721-9444 

References  

1. Kusuda S, Bennett MV, Gould JB, et al. Comparative analysis of necrotizing enterocolitis in preterm infants born in Japan and born to mothers of Japanese ethnicity in California. Sci Rep. 2025;15:9943. doi:10.1038/s41598-025-92393-y
2. Isayama T. The clinical management and outcomes of extremely preterm infants in Japan: past, present, and future. Transl Pediatr. 2019;8(3):199-211. doi:10.21037/tp.2019.07.10 
3. Data on file; estimated number of premature infants fed Prolacta’s products from January 2007 to May 2025. 
4. Ozturk G, Paviani B, Rai R, et al. Investigating milk fat globule structure, size, and functionality after thermal processing and homogenization of human milk. Foods. 2024;13(8):1242. doi:10.3390/foods13081242 
5. Liang N, Koh J, Kim BJ, et al. Structural and functional changes of bioactive proteins in donor human milk treated by vat-pasteurization, retort sterilization, ultra-high-temperature sterilization, freeze-thawing and homogenization. Front Nutr. Published online September 15, 2022. doi:10.3389/fnut.2022.926814 
6. Meredith-Dennis L, Xu G, Goonatilleke E, Lebrilla CB, Underwood MA, Smilowitz JT. Composition and variation of macronutrients, immune proteins, and human milk oligosaccharides in human milk from nonprofit and commercial milk banks. J Hum Lact. 2018;34(1):120-129. doi:10.1177/0890334417710635 

Logo – https://mma.prnasia.com/media2/1361490/Prolacta_Bioscience_Logo.jpg?p=medium600

Source

Establishing an Engineering-Level Core Technology for Next-Generation Semiconductor Manufacturing Applications

BEIJING, Feb. 18, 2026 /PRNewswire/ — Datasea Inc. (NASDAQ: DTSS) (“Datasea” or the “Company”), a Nevada-based technology company specializing in acoustic high-tech solutions and 5G+AI multimodal digitalization,

today announced that it has achieved a foundational research breakthrough in its ultrasonic-enhanced nanoscale precision control technology, representing a step-change in the Company’s technical architecture and underlying acoustic engineering capabilities. This milestone also marks the establishment of an engineering-level core technology architecture oriented toward next-generation semiconductor manufacturing applications.

The Company stated that this breakthrough reflects progress at the foundational research and architectural levels, rather than a single-point laboratory result. By systematically integrating ultrasonic enhancement mechanisms with ultra-precision composite manufacturing processes, Datasea is constructing a systems-level precision control architecture and related technical framework designed to address increasing complexity, stability, and nanoscale accuracy requirements in advanced semiconductor process environments.

This stage of R&D progress provides a technical foundation for subsequent engineering validation and application scenario exploration. The technology remains in the research and engineering validation stage and has not yet entered commercialization.

Strategic Significance for Next-Generation Semiconductor Manufacturing

As semiconductor nodes continue to shrink and process complexity increases, precision stability, surface uniformity, and nanoscale controllability are becoming increasingly critical technical factors across advanced manufacturing systems.

Datasea believes that expanding ultrasonic precision control into higher-complexity industrial environments demonstrates the scalability of its acoustic technology architecture beyond existing health-related and consumer-oriented applications.

This foundational research breakthrough reinforces the Company’s long-term strategic positioning in high-end industrial and advanced manufacturing sectors by leveraging its core acoustic technologies, while expanding the potential application scope of its underlying acoustic technology architecture.

Management Commentary

Ms. Zhixin Liu, Chief Executive Officer of Datasea, commented:

“This milestone represents a meaningful breakthrough at the foundational research level of our acoustic technology system. Our acoustic modulation capabilities have already been deployed across health, medical, and industrial domains. This latest research breakthrough marks an architecture-level elevation of those capabilities within high-precision industrial systems.

Integrating ultrasonic enhancement with nanoscale engineering demands multi-layer coordination and structural stability under extreme tolerances, underscoring the depth and scalability of our core acoustic architecture.

Strategically, this progression reflects the continued evolution of our acoustic technology across increasingly complex application environments and reinforces our long-term positioning within advanced manufacturing ecosystems.”

Next Steps

Datasea plans to continue refining this engineering-level architecture through further validation, performance modeling, and potential research collaborations. The Company will disclose additional developments as appropriate and in accordance with applicable regulatory requirements.

About Datasea Inc.

Datasea Inc. (“Datasea”) is a leading provider of products, services, and solutions for enterprise and retail customers in two innovative industries, acoustic high tech and 5G-AI multimodal digitalization. The Company’s advanced R&D technology serves as the core infrastructure and backbone for its products. Its 5G multimodal digital segment operates on a cloud architecture based on AI. Datasea leverages cutting-edge technologies, precision manufacturing, and ultrasonic, infrasound and directional sound technology in its acoustics business to combat viruses and prevent human infections, and it is also developing applications in medical ultrasonic cosmetology. In July 2023, Datasea established a wholly-owned subsidiary, Datasea Acoustics LLC, in Delaware, in a strategic move to enter the U.S. markets and to mark its global expansion plan. For additional information, please visit www.dataseainc.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook,” “objective” and similar terms. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond Datasea’s control, which may cause Datasea’s actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to Datasea as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Datasea’s filings with the SEC, which are available at www.sec.gov. Datasea does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Investor and Media Contact: 

Datasea Investor Relations
Email:  investorrelations@shuhaixinxi.com
                        sunhezhi@shuhaixinxi.com 

Precept Investor Relations LLC
David Rudnick
+1 646-694-8538
david.rudnick@preceptir.com

Source: Datasea Inc.

Source

YIWU, China, Feb. 18, 2026 /PRNewswire/ — A news report from Yiwu Media Convergence Center:

On the stage of the CMG(China Media Group) 2026 Year of the Horse Spring Festival Gala, Yiwu made a stunning eight-minute appearance, showcasing the city’s commercial vitality, inclusive spirit, and development miracle to a global audience. Though not its first time in the international spotlight, the performance once again ignited overseas fascination with this county-level Chinese city.

Across social media, Yiwu-related topics have remained highly visible, from the Milan Winter Olympics and the FIFA World Cup 2026 to the viral “KuKu Ma” (Crying Horse).

Supported by Yiwu’s foreign trade network, “KuKu Ma” swiftly went global. The Straits Times of Singapore analyzed the trend as evidence of Chinese manufacturing’s keen understanding of consumer emotion, highlighting industrial upgrading. PR Newswire noted that “Made in Yiwu” products continue to reach households worldwide.

Following the Yiwu sub-venue for the 2026 Spring Festival Gala broadcast, international interest surged. Viewers called Yiwu “Friendly”, “Inspirational”, and a “Dream Land”, with many saying, “I want to visit this year”. A foreign resident proudly called himself a “Yiwuise”, inspiring others to follow suit.

Before the Spring Festival, Yiwu’s promotional videos appeared on screens across 20 countries and five continents. From street markets to the “World Supermarket”, images of the Global Digital Trade Centre, new energy vehicle factories, and the China-Europe Railway Express showcased the city’s transformation worldwide.

Media outlets including The Manila Times, Vientiane Times, Singapore’s TNGlobal, and Germany’s FinanzNachrichten carried the story.

“Yiwu represents the future,” said Alex, a Finnish businessman who has worked in the city for over a decade. “People once thought it was just about small commodities, but now its own brands are going global. This is a Yiwu full of creativity and momentum for the times.”

Source

MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[¹⁸F]fluoroethyl)-L-tyrosine, ¹⁸F-FET), its glioma (brain cancer) imaging candidate.

Telix has been preparing the European and U.S. regulatory packages for TLX101-Px concurrently, bringing forward the European submission to meet an agreed filing date while aligning with aspects of the U.S. Food and Drug Administration (FDA) package to support the additional application. The submission covers major European markets^[1]. Telix is seeking to expand patient access to advanced brain imaging through a broad clinical label, reflective of current clinical practice guidelines^[2]. Submission of the U.S. New Drug Application (NDA) will follow.

In Europe, positron emission tomography (PET) imaging of glioma with ¹⁸F-FET (FET-PET) is currently performed under physician-supervised use through hospital-based production at a limited number of sites. However, there is currently no generally available commercial product in Europe that ensures consistent quality and access for glioma imaging, an acute and immediate need^[3]. Telix aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications. TLX101-Px is also being developed as a patient selection and response assessment tool for Telix’s glioblastoma therapy candidate TLX101-Tx (iodofalan ¹³¹I), which has been granted orphan drug designation in Europe and the U.S. and is the subject of the Phase 3 IPAX-BrIGHT trial in patients with recurrent glioblastoma, launching in multiple European countries^[4].

Philipp Lohmann, Group Leader Digital Translational Neuroimaging at Forschungszentrum Jülich research center in Germany, commented, “FET-PET imaging is already used in clinical practice in Europe for the evaluation of gliomas, and plays a critical role in treatment decision making. This applies particularly in the post-therapy setting, where conventional MRI^[5] alone can be limited in its ability to distinguish tumor progression from treatment-related changes. Having widespread access to TLX101-Px has potential to provide clinicians with greater biological insight, supporting more confident and timely management of patients with brain tumors.”

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, added, “We see a compelling opportunity in Europe to broaden access to authorized targeted radiopharmaceuticals for brain cancer imaging and therapy, and as such this submission is an important milestone for Telix. The strategic value of this submission is particularly relevant to establishing widespread glioma imaging as part of our corresponding therapeutic development program. We have been able to utilize aspects of our FDA package to expedite the European filing, which has been submitted in accordance with a pre-defined date agreed with the regulator, with the U.S. resubmission to follow.”

About glioma in Europe

In Europe, approximately 67,500 brain and central nervous system tumors are diagnosed every year^[6], with gliomas accounting for approximately 30% of these, and up to 80% of all malignant brain tumors^[7]. There is a critical unmet need to improve the diagnosis and management of gliomas, which are the most common primary brain tumors of the central nervous system, particularly in the post-treatment setting⁵. Conventional MRI imaging techniques have several limitations, including a lack of biological specificity, dependency on blood-brain barrier disruption, and an inherent inability to differentiate between tumor progression or treatment-related causes. This can yield inconclusive results and delay time-sensitive treatment decisions^[8]. With low survival rates and the need to make rapid decisions, precision imaging is paramount⁵. Subject to regulatory approval, TLX101-Px has the potential to address this need, enabling patients in Europe to receive greater clarity in their diagnosis and treatment decision making.

About TLX101-Px

TLX101-Px (O-(2-[¹⁸F]fluoroethyl)-L-tyrosine) is Telix’s PET imaging candidate for the characterization of glioma. TLX101-Px targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). This enables TLX101-Px to be potentially utilized as a complementary diagnostic agent to TLX101-Tx (iodofalan ¹³¹I), Telix’s LAT1-targeting investigational glioblastoma (GBM) therapy, currently under investigation in Telix’s IPAX-2^[9] and IPAX-BrIGHT⁶ studies. TLX101-Px and TLX101-Tx have not received a marketing authorization in any jurisdiction. In relevant European markets, the proposed brand name for TLX101-Px is “Pixlumi®”. Brand name and commercial launch are subject to final regulatory approval.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

Source

AI’s future depends on protecting creativity, building trust, and strengthening value for creators, MPA chairman declares

DELHI, India, Feb. 17, 2026 /PRNewswire/ — On February 16, the opening day of India’s AI Impact Summit, Charles Rivkin, Chairman and CEO of the Motion Picture Association (MPA), joined Shri Ashwini Vaishnaw, Minister for Information & Broadcasting (MIB), Electronics & Information Technology (MeitY), and Railways, Government of India, for a fireside conversation on the future of Artificial Intelligence (AI) and the creative economy.

Both leaders acknowledged that AI represents a new and exciting frontier for the global creative industries – sectors with a long and proven history of embracing transformative technologies in pursuit of creative excellence.

“AI can and must be used to expand creativity in a responsible way,” Rivkin said. “Our member studios are at the forefront of this transformation, recognising the immense potential of AI to enhance storytelling while keeping human creativity at the heart of filmmaking. Strong copyright frameworks are indispensable — they anchor a vibrant creative economy, drive investment in the media & entertainment sector and turn creative ingenuity and storytelling into world-class cultural exports.”

“I commend the Government of India for convening this forum at such a consequential moment,” he added.

Speaking about the intersection of the creative economy and AI, Minister Vaishnaw said: “We believe that human creativity is the most important thing that we have in our entire civilisation. So we must protect it. We must make sure that any system that protects human creativity and enhances it, is a better system. There shouldn’t be a dilutive effect. There should be more of a complementing impact on human creativity.”

The event, Rewarding Our Creative Future in the Age of AI – Strengthening India Through Innovation, Trust and Talent, was organised by the MPA in partnership with the Federation of Indian Chambers of Commerce and Industry (FICCI), MIB, and Creative First, with support from a broad cross-section of film, television and streaming industry organisations.

The AI & Creative Economy track directly supports some of the key pillars underpinning the AI Impact Summit, especially around human capital, trusted AI, and AI for economic and social good. The program builds on the momentum of last year’s WAVES Summit and serves as a bridge to next year’s gathering, reinforcing India’s leadership at the convergence of creativity, technology and culture, and recognizes MPA member studios’ continued contribution to the growth of the screen industry.

The AI Impact Summit, convened at the invitation of Prime Minister Narendra Modi, is positioned as the first major global AI gathering in the southern hemisphere. It has drawn heads of state from 20 nations, ministerial delegations from 45 countries, and CEOs from the biggest technology companies.

Following Monday’s fireside conversation, MPA convened an industry discussion during which production and VFX experts underscored how AI is an active collaborator across the content value chain. The panel session – Where Content Meets Code; Reimagining Storytelling – featured Prasoon Joshi, Poet, Screenwriter, advertising legend and Chairperson of the Central Board of Film Certification; Sushant Sreeram, Head of Marketing & SVOD at JioStar; Tyrone Estephan, Managing Director at Alt.VFX; Merzin Tavaria, Co-Founder and President – Global Production & Operations at DNEG; Niraj Ruparel, Creative Technology Lead at WPP and WPP Media India; and Vatsal Sheth, Co-Founder and CEO of Prismix Studios.

The MPA’s program exploring the intersection of AI and the creative economy will continue throughout 2026 across key markets.

Images from the event are available here.

About The Motion Picture Association

The Motion Picture Association (MPA) serves as the leading voice and advocate of the motion picture, home video, and television industries. It works in every corner of the globe to advance the creative industry, protect its members’ content across all screens, defend the creative and artistic freedoms of storytellers, and support innovative distribution models that bring an expansion of viewing choices to audiences around the world. Its member studios are: Netflix, Paramount Pictures, Prime Video & Amazon MGM Studios, Sony Pictures, Universal Studios, The Walt Disney Studios, and Warner Bros. Discovery. Charles Rivkin is Chairman and CEO.

Source